144 related articles for article (PubMed ID: 26610096)
1. Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.
Victoni T; Gicquel T; Bodin A; Daude M; Tenor H; Valença S; Devillier P; Porto LC; Lagente V; Boichot E
Int Immunopharmacol; 2016 Jan; 30():1-8. PubMed ID: 26610096
[TBL] [Abstract][Full Text] [Related]
2. Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells.
Victoni T; Gleonnec F; Lanzetti M; Tenor H; Valença S; Porto LC; Lagente V; Boichot E
PLoS One; 2014; 9(1):e85243. PubMed ID: 24416369
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast improves corticosteroid resistance COPD bronchial epithelial cells stimulated with toll like receptor 3 agonist.
Milara J; Morell A; Ballester B; Sanz C; Freire J; Qian X; Alonso-Garcia M; Morcillo E; Cortijo J
Respir Res; 2015 Feb; 16(1):12. PubMed ID: 25652132
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-4 inhibition augments human lung fibroblast vascular endothelial growth factor production induced by prostaglandin E2.
Ikari J; Michalski JM; Iwasawa S; Gunji Y; Nogel S; Park JH; Nelson AJ; Farid M; Wang X; Schulte N; Basma H; Toews ML; Feghali-Bostwick C; Tenor H; Liu X; Rennard SI
Am J Respir Cell Mol Biol; 2013 Oct; 49(4):571-81. PubMed ID: 23656623
[TBL] [Abstract][Full Text] [Related]
5. The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro.
Jones NA; Boswell-Smith V; Lever R; Page CP
Pulm Pharmacol Ther; 2005; 18(2):93-101. PubMed ID: 15649851
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
8. Direct Inhibitory Effect of the PDE4 Inhibitor Roflumilast on Neutrophil Migration in Chronic Obstructive Pulmonary Disease.
Dunne AE; Kawamatawong T; Fenwick PS; Davies CM; Tullett H; Barnes PJ; Donnelly LE
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):445-453. PubMed ID: 30395484
[TBL] [Abstract][Full Text] [Related]
9. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast Increases Bacterial Load and Dissemination in a Model of Pseudomononas Aeruginosa Airway Infection.
Kasetty G; Papareddy P; Bhongir RK; Egesten A
J Pharmacol Exp Ther; 2016 Apr; 357(1):66-72. PubMed ID: 26865680
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes.
Totani L; Amore C; Di Santo A; Dell'Elba G; Piccoli A; Martelli N; Tenor H; Beume R; Evangelista V
J Thromb Haemost; 2016 Jan; 14(1):191-204. PubMed ID: 26484898
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
13. Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.
Kubo S; Kobayashi M; Iwata M; Miyata K; Takahashi K; Shimizu Y
Int Immunopharmacol; 2012 Jan; 12(1):59-63. PubMed ID: 22041526
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of PDE4 and PI3Kδ modulates the inflammatory component involved in the progression of chronic obstructive pulmonary disease.
Dinavahi SS; Nyayapathy S; Perumal Y; Dharmarajan S; Viswanadha S
Drug Res (Stuttg); 2014 Apr; 64(4):214-9. PubMed ID: 24105104
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast inhibits lipopolysaccharide-induced tumor necrosis factor-α and chemokine production by human lung parenchyma.
Buenestado A; Chaumais MC; Grassin-Delyle S; Risse PA; Naline E; Longchampt E; Tenor H; Devillier P
PLoS One; 2013; 8(9):e74640. PubMed ID: 24066150
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid Receptor α Mediates Roflumilast's Ability to Restore Dexamethasone Sensitivity in COPD.
Reddy AT; Lakshmi SP; Banno A; Reddy RC
Int J Chron Obstruct Pulmon Dis; 2020; 15():125-134. PubMed ID: 32021151
[TBL] [Abstract][Full Text] [Related]
17. The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients.
Lea S; Metryka A; Li J; Higham A; Bridgewood C; Villetti G; Civelli M; Facchinetti F; Singh D
Cytokine; 2019 Nov; 123():154739. PubMed ID: 31319374
[TBL] [Abstract][Full Text] [Related]
18. Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.
Tannheimer SL; Sorensen EA; Haran AC; Mansfield CN; Wright CD; Salmon M
Pulm Pharmacol Ther; 2012 Apr; 25(2):178-84. PubMed ID: 22306235
[TBL] [Abstract][Full Text] [Related]
19. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: a novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease.
Moodley T; Wilson SM; Joshi T; Rider CF; Sharma P; Yan D; Newton R; Giembycz MA
Mol Pharmacol; 2013 Apr; 83(4):894-906. PubMed ID: 23389862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
